About Bryn Pharma
Bryn Pharma is a private company based in Lebanon, New Jersey. It has reported $127,403,450 raised in six offerings on Form D since July 2018.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Apr 10, 2025 | Aug 14, 2025 | $4,692,830fully sold | 105 | $44,694 | Convertible (equity-linked) debtRule 506(b) | Form D ↗ |
| Apr 25, 2023 | May 10, 2023amended Jul 5, 2023 | $26,724,100of $30.0M target | 105 | $254K | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Jul 6, 2021 | Jul 20, 2021amended Oct 11, 2022 | $43,510,775of $50.0M target | 246 | $176K | EquityRule 506(b) | Form D/A ↗2 earlier filings |
| Oct 18, 2019 | Nov 4, 2019amended Jun 22, 2020 | $26,000,000of $35.0M target | 127 | $204K | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Feb 8, 2019 | Feb 21, 2019 | $17,223,780of $18.0M target | 77 | $223K | EquityRule 506(b) | Form D ↗ |
| Jul 16, 2018 | Jul 30, 2018 | $9,251,965of $15.0M target | 72 | $128K | EquityRule 506(b) | Form D ↗ |
| Total, six offerings | $127,403,450 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Bryn Pharma's Form D filed Aug 14, 2025.
Earlier filings also listed William Humphries (director, last listed Jul 2023), Sandy Loreaux (executive officer and director, last listed Jul 2023), David Dworaczyk (executive officer and director, last listed Jul 2023), Robert Yanez (executive officer, last listed Oct 2022), Kate Grell (director, last listed Oct 2022), Stephen Beckman (executive officer, last listed Jun 2020), Dale Sander (executive officer, last listed Jun 2020) and Rick Schaden (director, last listed Jul 2018).